Tirzepatide : Approved in 2022 (Mounjaro) and 2024 (Zepbound), its NCE exclusivity runs to May 2027, delaying generic filings until 2026
Targets and breaks down stored fat while preserving lean muscle a sculpting peptide for refined body composition
But its GI side effect profile is also the most aggressive, with nausea rates reaching 40% to 50% and vomiting rates significantly higher than cagrilintide monotherapy
S2CID 94929244
Since obesity is associated with an increased risk of cardiovascular disease, the ongoing SELECT study is investigating whether once-weekly semaglutide 2.4 mg will reduce the risk of having cardiovascular events in patients with overweight or obesity and with prior cardiovascular disease [61]
Skin water content, transepidermal water loss (TEWL), skin elasticity, skin thickness, and the level of NMF constituents were determined in the SC at baseline and then at 12 weeks